Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data

ASCO: Takeda touts ‘tremendous potential’ of Innovent’s PD-1/IL-2 bispecific after seeing survival data

  • June 1, 2026

Takeda and Innovent’s long-term follow-up data from an early study of their collaborative PD-1/IL-2 bispecific colors the “tremendous potential” of the asset, Takeda’s P.K. Morrow said in an interview.

Leave A Comment

Fields (*) Mark are Required